VCYT vs ACNB

For growth investors, ACNB Corporation (ACNB) is the stronger pick with 28.

9% revenue growth year-over-year, versus 16. 0% for Veracyte, Inc. (VCYT). ACNB Corporation (ACNB) offers the better valuation at 14. 7x trailing P/E (9. 9x forward), making it the more compelling value choice. Analysts rate Veracyte, Inc. (VCYT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACNB Corporation (ACNB) is the cheapest at 14.

7x versus Veracyte, Inc. at 49. 7x. On forward P/E, ACNB Corporation is actually cheaper at 9. 9x.

Over the past 5 years, ACNB Corporation (ACNB) delivered a total return of +105.

0%, compared to -8. 1% for Veracyte, Inc. (VCYT). Over 10 years, the gap is even starker: VCYT returned +638. 4% versus ACNB's +188. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACNB Corporation (ACNB) is the lower-risk stock at 0.

68β versus Veracyte, Inc. 's 1. 52β — meaning VCYT is approximately 123% more volatile than ACNB relative to the S&P 500. On balance sheet safety, Veracyte, Inc. (VCYT) carries a lower debt/equity ratio of 3% versus 78% for ACNB Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACNB Corporation (ACNB) is pulling ahead at 28.

9% versus 16. 0% for Veracyte, Inc. (VCYT). On earnings-per-share growth, the picture is similar: Veracyte, Inc. grew EPS 164. 5% year-over-year, compared to -3. 5% for ACNB Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACNB Corporation (ACNB) is the more profitable company, earning 21.

7% net margin versus 12. 8% for Veracyte, Inc. — meaning it keeps 21. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACNB leads at 27. 3% versus 14. 3% for VCYT. At the gross margin level — before operating expenses — ACNB leads at 73. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACNB Corporation (ACNB) trades at 9.

9x forward P/E versus 24. 6x for Veracyte, Inc. — 14. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACNB: 9. 4% to $58. 00.

In this comparison, ACNB (2.

6% yield) pays a dividend. VCYT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, ACNB Corporation (ACNB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

68), 2. 6% yield, +188. 7% 10Y return). Veracyte, Inc. (VCYT) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACNB: +188. 7%, VCYT: +638. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (VCYT (Healthcare) and ACNB (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

ACNB pays a dividend while VCYT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.